Your browser doesn't support javascript.
loading
Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries.
Holko, Przemyslaw; Kawalec, Pawel; Sajak-Szczerba, Magdalena; Avedano, Luisa; Mossakowska, Malgorzata.
Afiliación
  • Holko P; Department of Nutrition and Drug Research, Institute of Public Health, Jagiellonian University Medical College, Skawinska 8, 31-066, Krakow, Poland. p.holko@uj.edu.pl.
  • Kawalec P; Department of Nutrition and Drug Research, Institute of Public Health, Jagiellonian University Medical College, Skawinska 8, 31-066, Krakow, Poland.
  • Sajak-Szczerba M; European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.
  • Avedano L; Polish Association Supporting People With Inflammatory Bowel Disease "J-Elita", Warsaw, Poland.
  • Mossakowska M; European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium.
Eur J Health Econ ; 24(7): 1073-1083, 2023 Sep.
Article en En | MEDLINE | ID: mdl-36261612
ABSTRACT

BACKGROUND:

There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, we compared patient costs of IBDs between 12 European countries.

METHODS:

A questionnaire-based study was conducted among adult patients with IBD. Data on patient characteristics and out-of-pocket expenses were anonymously collected. Ordered logit regression models were used to analyse the responses provided by patients. The results were adjusted for confounders and multiplicity.

RESULTS:

The questionnaires obtained from 3687 patients were analysed. Patients with comorbidities and active disease indicated higher out-of-pocket expenses than those without comorbidities and with disease in remission, respectively. Compared with other IBD, patients with ulcerative colitis indicated higher expenses on medications prescribed or recommended by physicians [odds ratio (OR) 1.99, 95% CI 1.48-2.67]. Expenses on dietary supplements, special diet or equipment, ostomy pouches, and transportation to a medical facility differed slightly between patients at different ages and were lower among men than among women (OR 0.71, 95% CI 0.54-0.93). The expenses differed significantly between countries. An adjusted mean patient cost per month varied from €77 (patient with Crohn disease in remission from Denmark) to €376 (patient with active ulcerative colitis from Romania). Compared with active disease, patients with IBD in remission had a lower out-of-pocket cost by 29-62% (€10-€22 monthly; p < 0.001).

CONCLUSIONS:

The study revealed a high relevance of the out-of-pocket cost of IBD in the context of economic evaluation and a high variability of the cost between countries.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Colitis Ulcerosa / Enfermedad de Crohn Tipo de estudio: Health_economic_evaluation / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Eur J Health Econ Asunto de la revista: SAUDE PUBLICA / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Polonia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Colitis Ulcerosa / Enfermedad de Crohn Tipo de estudio: Health_economic_evaluation / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Eur J Health Econ Asunto de la revista: SAUDE PUBLICA / SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Polonia